HU9700039D0 - New oral pharmaceutical formulation containing magnesium salt of omeprazole - Google Patents

New oral pharmaceutical formulation containing magnesium salt of omeprazole

Info

Publication number
HU9700039D0
HU9700039D0 HU9700039A HU9700039A HU9700039D0 HU 9700039 D0 HU9700039 D0 HU 9700039D0 HU 9700039 A HU9700039 A HU 9700039A HU 9700039 A HU9700039 A HU 9700039A HU 9700039 D0 HU9700039 D0 HU 9700039D0
Authority
HU
Hungary
Prior art keywords
omeprazole
pharmaceutical formulation
formulation containing
magnesium salt
oral pharmaceutical
Prior art date
Application number
HU9700039A
Other languages
Hungarian (hu)
Other versions
HUT78132A (en
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of HU9700039D0 publication Critical patent/HU9700039D0/en
Publication of HUT78132A publication Critical patent/HUT78132A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HU9700039A 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole HUT78132A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9400679 1994-07-08
PCT/SE1995/000816 WO1996001622A1 (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole

Publications (2)

Publication Number Publication Date
HU9700039D0 true HU9700039D0 (en) 1997-02-28
HUT78132A HUT78132A (en) 2000-06-28

Family

ID=20393105

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9700039A HUT78132A (en) 1994-07-08 1995-07-03 New oral pharmaceutical formulation containing magnesium salt of omeprazole

Country Status (15)

Country Link
EP (1) EP0768872A1 (en)
KR (1) KR970704426A (en)
BR (1) BR9508261A (en)
CA (1) CA2193681A1 (en)
CZ (1) CZ379596A3 (en)
EE (1) EE03378B1 (en)
FI (1) FI970058A (en)
HU (1) HUT78132A (en)
IS (1) IS4398A (en)
MX (1) MX9700152A (en)
NO (1) NO970036D0 (en)
NZ (1) NZ289958A (en)
PL (1) PL181265B1 (en)
SK (1) SK166096A3 (en)
WO (1) WO1996001622A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5900258A (en) * 1996-02-01 1999-05-04 Zeolitics Inc. Anti-bacterial compositions
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704869D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9802973D0 (en) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
EP1133987A1 (en) * 2000-03-09 2001-09-19 Ian Whitcroft Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor
CA2413923A1 (en) * 2000-03-09 2001-09-13 Andrew Ilchyshyn Treatment of inflammatory dermatoses comprising erythromycin or clarythromycin metronidazole and a gastrointestinal hydrogen pump inhibitor
WO2004035052A1 (en) 2002-10-16 2004-04-29 Takeda Pharmaceutical Company Limited Stable solid preparations
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060051421A1 (en) * 2004-06-15 2006-03-09 Nava Shterman Stable pharmaceutical formulations of benzimidazole compounds
CN105106168B (en) * 2015-08-19 2018-03-06 德州德药制药有限公司 A kind of esomeprazole magnesium intestines capsule and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0768125B2 (en) * 1988-05-18 1995-07-26 エーザイ株式会社 Oral formulation of acid labile compounds
SE9302395D0 (en) * 1993-07-09 1993-07-09 Ab Astra NEW PHARMACEUTICAL FORMULATION
SE9302396D0 (en) * 1993-07-09 1993-07-09 Ab Astra A NOVEL COMPOUND FORM

Also Published As

Publication number Publication date
EE9700014A (en) 1997-06-16
WO1996001622A1 (en) 1996-01-25
NO970036L (en) 1997-01-06
NZ289958A (en) 1998-09-24
BR9508261A (en) 1997-12-23
PL318464A1 (en) 1997-06-09
FI970058A0 (en) 1997-01-07
IS4398A (en) 1996-12-17
MX9700152A (en) 1997-04-30
NO970036D0 (en) 1997-01-06
CA2193681A1 (en) 1996-01-25
CZ379596A3 (en) 1997-08-13
AU2994795A (en) 1996-02-09
KR970704426A (en) 1997-09-06
EP0768872A1 (en) 1997-04-23
HUT78132A (en) 2000-06-28
SK166096A3 (en) 1997-09-10
WO1996001622A8 (en) 1999-12-23
EE03378B1 (en) 2001-04-16
AU695723B2 (en) 1998-08-20
PL181265B1 (en) 2001-06-29
FI970058A (en) 1997-01-07

Similar Documents

Publication Publication Date Title
IL127955A0 (en) Pharmaceutical composition containing acid addition salt of basic drug
HU9700039D0 (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole
EG24044A (en) pharmaceutical formulation of omeprazole
IL115097A0 (en) Pharmaceutical compositions adapted for oral administration
HUP9903407A3 (en) Oral pharmaceutical preparation containing ibandronat
IL118637A0 (en) Oral pharmaceutical compositions of S(+)-ibuprofen
IL116957A0 (en) Substituted heterocyclic compounds their preparation and pharmaceutical compositions containing them
IL118636A (en) Oral pharmaceutical compositions of S(+)-etodolac
HU9502520D0 (en) Pharmaceutical use of substituted 4-phenyl-6-amino-nicotinic acid derivatives
IL118250A0 (en) 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof and pharmaceutical compositions containing them
IL95158A0 (en) Pharmaceutical composition for oral administration containing n-acetyl-cysteine
HUP0001084A3 (en) Modified release oral pharmaceutical composition containing 5-asa for the treatment of bowel diseases
IL114673A (en) Pharmaceutical compositions containing protein for oral administration
IL134958A0 (en) Serotonin containing formulation for oral administration and method of use
NZ307370A (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
ITMI932014A0 (en) EFFERVESCENT ORAL PHARMACEUTICAL COMPOSITIONS CONTAINING ESTRONE
HUP9701293A3 (en) New salts without unsavoury taste and pharmaceutical compositions containing them
IL123424A0 (en) Heterocyclic compounds their preparation and pharmaceutical compositions containing them
HU9302821D0 (en) Pharmaceutical compositions containing 3-substituted-2-oxindole-1-carboxamide as medical agent
HUP9901126A3 (en) Pharmaceutical composition for external use containing nimesulide and process for the preparation thereof
IL114621A0 (en) Derivatives of 6-fluoro-8-difluoromethoxy-substituted quinolonecarboxylic acids theit preparation and pharmaceutical compositions containing them
IL130820A0 (en) Pharmaceutical composition for oral treatment of multiple sclerosis
EG19689A (en) New pharmaceutical preparation for oral use
SI0927031T1 (en) Pharmaceutical preparation containing nimesulide for oral administration
IL137496A0 (en) Dosage form and pharmaceutical kit for increasing the oral availablity of pharmaceutical agents

Legal Events

Date Code Title Description
DFC4 Cancellation of temporary protection due to refusal